Finance & valuation

Latest content

How flawed fintechs are running out of gas

Plummeting fintech stock prices are leading to an urgent re-evaluation of certain business models in the space. However, a closer look at intangible assets might hold the solution to this dilemma.

28 September 2022

Meet 2022’s IP Hall of Fame inductees

Following a selection process that ran between March and May, IAM announced that four new individuals had been chosen to join the IP Hall of Fame in 2022: Pravin Anand, Justice Stephen Breyer, Louis Foreman and James Malackowski. They were officially inducted at this year’s IPBC Global in June.

14 September 2022

$600 million BlackBerry patent deal still alive despite exit of key financial backer

Third Eye Capital syndicate due to provide $400 million for the purchase of the portfolio pulls out, but replacements are said to be on hand

31 August 2022

IP-backed lending is becoming a serious option for many companies

Utilising patents as collateral for credit can save expense or even provide capital when VC or traditional lenders refuse

05 August 2022

The contribution patents make to enterprise value

No commonly used valuation methods are much help at putting a number on an entire portfolio unless there is a specific transaction on the horizon. Cipher’s Nigel Swycher and Steve Harris suggest an original methodology to fill this gap

03 August 2022

IP tax strategies come under fire from US senators

Legislators put pharma companies under the microscope and blame a law signed by President Trump in 2017 for patent-based payment mitigation

01 August 2022

How the IVSC is preparing to accelerate intangible assets valuation in Asia

After establishing an office in Asia, the CEO of the International Valuation Standards Council expands on plans to escalate intangible assets valuation in the region

26 July 2022

Lessons from China's $46 billion IP financing market

After over a decade and the involvement of various stakeholders, China achieved $46 billion in IP financing in 2021

08 July 2022

Pfizer to commercialise its IP with the help of trailblazing Roivant approach

The partnership is aimed at helping the pharma giant to moentise deprioritised IP in the autoimmune space

04 July 2022

Why IP valuation in Asia has yet to take off

Although various government-led programmes have emerged over the years to encourage activity in the field, writes Joyce Ng, professionals reveal that a lack of transaction data and an absence of corporate buy-in is preventing it from going mainstream

22 June 2022

Unlock unlimited access to all IAM content